Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FURIN | P09958 | 5/20 | 0.38 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.38 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711520 | 1.00 | C3AR1 (0.44) | C3AR1CTDSP1NOD1FOLH1SMN1; SMN2 | |
| SCHEMBL23393940 | 0.90 | SIRT5 (0.39) | C3AR1NOD1SMN1; SMN2FURINKMT2A | |
| SCHEMBL22045351 | 0.89 | FURIN (0.39) | C3AR1SMN1; SMN2FURIN | |
| SCHEMBL29977834 | 0.89 | NPY4R (0.39) | NOD1FOLH1SMN1; SMN2FURINGNPAT | |
| SCHEMBL21915057 | 0.89 | C3AR1 (0.34) | C3AR1CTDSP1SMN1; SMN2FURINKMT2A | |
| SCHEMBL23736705 | 0.89 | FURIN (0.36) | C3AR1SMN1; SMN2FURINKMT2APOLB | |
| SCHEMBL21103418 | 0.89 | SIRT5 (0.36) | C3AR1NOD1SMN1; SMN2FURINKMT2A | |
| SCHEMBL20795891 | 0.89 | FURIN (0.36) | C3AR1SMN1; SMN2FURINKMT2APOLB | |
| SCHEMBL20159819 | 0.89 | FURIN (0.36) | C3AR1SMN1; SMN2FURINKMT2APOLB | |
| SCHEMBL24490420 | 0.89 | C3AR1 (0.34) | C3AR1CTDSP1SMN1; SMN2FURINKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140917-A1 | ANTI-CD40 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海盛迪医药有限公司 | 2024-07-04 | — | — | WO | claimed |
| EP-4289857-A1 | DRUG CONJUGATE OF GLUCOCORTICOID RECEPTOR AGONIST, AND APPLICATION THEREOF IN MEDICINE | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-12-13 | — | — | EP | claimed |
| CN-116761820-A | Pharmaceutical conjugates of glucocorticoid receptor agonists and their use in medicine | 上海森辉医药有限公司 | 2023-09-15 | — | — | CN | claimed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | claimed |
| WO-2022166779-A1 | DRUG CONJUGATE OF GLUCOCORTICOID RECEPTOR AGONIST, AND APPLICATION THEREOF IN MEDICINE | 上海森辉医药有限公司 | 2022-08-11 | — | — | WO | claimed |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4703388-A1 | ANTI-TF ANTIBODY AND ANTI-TF ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | IMMUNOME INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260022193-A1 | METHODS OF TREATMENT USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 | ZYMEWORKS BC INC (CA) | 2026-01-22 | — | — | US | disclosed |
| EP-4674437-A1 | ANTI-DLL3 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | Suzhou Suncadia Biopharmaceuticals Co., Ltd. (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-12435157-B2 | Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancers | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250276077-A1 | EPHA2 ANTIBODIES | IMMUNOME INC (US) | 2025-09-04 | — | — | US | disclosed |
| EP-2344478-A2 | NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2011-07-20 | — | — | EP | disclosed |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | SYNTARGA B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| WO-2010062171-A2 | NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2010-06-03 | — | — | WO | disclosed |
| EP-2173739-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2010-04-14 | — | — | EP | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
| WO-2009017394-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2009-02-05 | — | — | WO | disclosed |
| EP-1994000-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | C3AR1 933/4885CTDSP1 54/4885NOD1 3209/4885 |
| US-20250276077-A1 | EPHA2 ANTIBODIES | EPHA2, EPHB2, EPHA1 | C3AR1 56/4885CTDSP1 3603/4885NOD1 2822/4885 |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | H1-10, IGSF11, CD99 | C3AR1 985/4885CTDSP1 3604/4885NOD1 4521/4885 |
| US-20260022193-A1 | METHODS OF TREATMENT USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 | IGSF11, ERBB2, PDCD1LG2 | C3AR1 1977/4885CTDSP1 721/4885NOD1 3684/4885 |
| US-12435157-B2 | Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancers | AURKC, AURKB, BSG | C3AR1 1264/4885CTDSP1 2339/4885NOD1 2952/4885 |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | B4GALT1, ST6GAL1, GALNT3 | C3AR1 1473/4885CTDSP1 4189/4885NOD1 1878/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | C3AR1 4306/4885CTDSP1 1714/4885NOD1 3558/4885 |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | PCNA, TOP1, TOP2B | C3AR1 452/4885CTDSP1 359/4885NOD1 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.